These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 20151476)
21. [Methodologic and ethical implications of immunosuppressive therapy in multiple sclerosis]. Szobor A Orv Hetil; 1984 Mar; 125(11):673. PubMed ID: 6700975 [No Abstract] [Full Text] [Related]
22. [Immunosuppressive therapy of multiple sclerosis using cyclophosphamide with few side effects]. Kornhuber HH; Mauch E Dtsch Med Wochenschr; 1986 Nov; 111(46):1778. PubMed ID: 3780443 [No Abstract] [Full Text] [Related]
23. [Development of oral therapies for multiple sclerosis--fingolimod, cladribine and other drugs]. Hecht B Med Monatsschr Pharm; 2010 Apr; 33(4):120-30; quiz 131-2. PubMed ID: 20429402 [TBL] [Abstract][Full Text] [Related]
24. Disease modification in multiple sclerosis. Sheerani M J Pak Med Assoc; 2003 Dec; 53(12):612-5. PubMed ID: 14765944 [No Abstract] [Full Text] [Related]
25. Immunosuppression for multiple sclerosis. N Engl J Med; 1983 Jul; 309(4):239-41. PubMed ID: 6866042 [No Abstract] [Full Text] [Related]
26. [Immunosuppressive treatment in multiple sclerosis]. Vermeulen M; Zegerius L; van Crevel H Ned Tijdschr Geneeskd; 1987 Jan; 131(3):93-6. PubMed ID: 3821989 [No Abstract] [Full Text] [Related]
27. The use of disease-modifying agents in multiple sclerosis--by the Canadian Network of MS Clinics. O'Connor P; Devonshire V; Can J Neurol Sci; 2008 May; 35(2):127-32. PubMed ID: 18574923 [No Abstract] [Full Text] [Related]
28. [Treatment of multiple sclerosis--now and in future. The Danish Multiple Sclerosis Society and the Danish Multiple Sclerosis Group]. Sellebjerg FT; Sørensen PS; Ugeskr Laeger; 2007 Mar; 169(12):1121. PubMed ID: 17394832 [No Abstract] [Full Text] [Related]
30. [Immunological treatments in multiple sclerosis]. Abramsky O Harefuah; 1981 Aug; 101(3-4):73-4. PubMed ID: 7319393 [No Abstract] [Full Text] [Related]
31. [Immunosuppressive therapy]. Purice S Stud Cercet Med Interna; 1973; 14(3):209-16. PubMed ID: 4574134 [No Abstract] [Full Text] [Related]
32. [Pharmacologic constraints imposed by the blood-brain barrier: the example of multiple sclerosis]. Jolliet P Rev Neurol (Paris); 2000 Jul; 156(6-7):681-3. PubMed ID: 10891808 [No Abstract] [Full Text] [Related]
33. Glatiramer acetate in the treatment of multiple sclerosis. Miller AE Neurol Clin; 2005 Feb; 23(1):215-31, viii. PubMed ID: 15661095 [No Abstract] [Full Text] [Related]
34. [Glatiramer for relapsing-remitting multiple sclerosis]. Hennemann A Med Monatsschr Pharm; 2002 Apr; 25(4):141-2. PubMed ID: 12017128 [No Abstract] [Full Text] [Related]
35. Neuroimmunology of multiple sclerosis and experimental allergic encephalomyelitis. Stuerzebecher S; Martin R Neuroimaging Clin N Am; 2000 Nov; 10(4):649-68 ,vii-viii. PubMed ID: 11359717 [TBL] [Abstract][Full Text] [Related]
37. Treatment of children and adolescents with multiple sclerosis. Banwell B Expert Rev Neurother; 2005 May; 5(3):391-401. PubMed ID: 15938672 [TBL] [Abstract][Full Text] [Related]
38. [Interaction of central nervous system local immunity and systemic immunity during multiple sclerosis]. Tourtellotte WW Rev Neurol (Paris); 1972 Nov; 127(5):497-504. PubMed ID: 4588993 [No Abstract] [Full Text] [Related]
39. [Intensive immunosuppressive treatment of chronic progressive multiple sclerosis]. Hommes OR Ned Tijdschr Geneeskd; 1978 Oct; 122(41):1545-51. PubMed ID: 358004 [No Abstract] [Full Text] [Related]
40. The limitations of immunosuppressant therapy in Multiple Sclerosis. Sedal L J Clin Neurosci; 2000 Nov; 7(6):563-4; discussion 564-5. PubMed ID: 11029245 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]